GlassScriptPhysician profile
Talha Farid
$21.42
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,513 · Consulting Fee: $1,000 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,512.76 |
| Consulting Fee | $1,000.00 |
| Education | $204.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,311.48 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $1,628.22 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $930.77 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $722.02 | 2022-2025 | |
| Genzyme Corporation | $702.14 | 2022-2025 | |
| Leo Pharma INC. | $552.78 | 2022-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $374.91 | 2023-2025 | Sotyktu |
| Pfizer INC. | $372.21 | 2022-2025 | |
| Ucb, INC. | $336.32 | 2022-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $208.17 | 2023-2025 | Ilumya, Winlevi, Blu-U |
| Janssen Scientific Affairs, LLC | $148.62 | 2022 | |
| Dermavant Sciences, INC. | $142.65 | 2023-2024 | Vtama |
| Amgen INC. | $115.82 | 2022-2024 | Otezla, Enbrel |
| Galderma Laboratories, L.P. | $98.73 | 2023-2025 | Nemluvio, Oracea |
| Janssen Biotech, INC. | $84.99 | 2024 | Tremfya |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.75 | 2022-2025 | Spevigo |
| Lilly USA, LLC | $80.33 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Sanofi-Aventis U.S. LLC | $66.99 | 2022 | |
| Incyte Corporation | $58.21 | 2023-2025 | Opzelura |
| Verrica Pharmaceuticals INC. | $40.24 | 2023 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $32.05 | 2024 | Jublia |
| Biofrontera INC. | $19.47 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $14.85 | 2025 | |
| Botanix Sb INC | $14.80 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talha Farid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.